At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Abundance of severe gum disease -- periodontitis -- may worsen disability for people with multiple sclerosis (MS), a chronic ...

New Swedish research finds that people with highest microplastics and PFAS levels face double the risk of multiple sclerosis ...

See why TG Therapeutics, Inc. earns a Buy rating, with insights on Briumvi's efficacy and market growth in multiple sclerosis ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

If gut bacteria are too similar to the protective layer of nerves, they can misdirect the immune system and cause it to attack its own nervous system. This mechanism can accelerate the progression of ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Sanofi (NASDAQ:SNY) said on December 15 that a US regulatory decision for its experimental multiple sclerosis drug will be ...

Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...